Oct 3 (Reuters) - Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases, the companies said on Tuesday. (Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
These proven wealth builders could be exactly what you're searching for right now.
Here's what could happen next to Microsoft shares.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
Baron, whose largest position is in Tesla, is betting the new shift in strategy for Tesla’s low-cost car will fill its increasingly empty factories.
Rooting for Donald Trump to fail has rarely been this profitable. Just ask a hardy band of mostly amateur Wall Street investors who have collectively made tens of millions of dollars over the past month by betting that the stock price of his social media business — Truth Social — will keep dropping despite massive buying by Trump loyalists and wild swings that often mirror the candidate’s latest polls, court trials and outbursts on Truth Social itself.